Andrew Vaillant

6100 Royalmount Ave
Montreal, QC H4P2R2, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D : Case reports.

Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D : Case reports.

Journal: Wiener klinische Wochenschrift

Published: February 02, 2026

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.

Journal: Journal of hepatology

Published: April 11, 2025

Functional Cure for Hepatitis B Virus: Challenges and Achievements.

Functional Cure for Hepatitis B Virus: Challenges and Achievements.

Journal: International journal of molecular sciences

Published: February 24, 2025

HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.

HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.

Journal: Antiviral research

Published: October 28, 2024

HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression.

HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression.

Journal: Viruses

Published: February 28, 2024

Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen.

Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen.

Journal: PloS one

Published: June 13, 2023

Novel fully automated prototype assays for specific detection of phosphorylated and non-phosphorylated Hepatitis B core antigens.

Novel fully automated prototype assays for specific detection of phosphorylated and non-phosphorylated Hepatitis B core antigens.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: March 27, 2023

Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure.

Rapid monophasic HBsAg decline during nucleic-acid polymer-based therapy predicts functional cure.

Journal: Hepatology communications

Published: March 23, 2023

Efficacy and Safety of Bepirovirsen in Hepatitis B.

Efficacy and Safety of Bepirovirsen in Hepatitis B.

Journal: The New England journal of medicine

Published: March 22, 2023

Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.

Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.

Journal: Viruses

Published: August 11, 2022

Bepirovirsen/GSK3389404: Antisense or TLR9 agonists?

Bepirovirsen/GSK3389404: Antisense or TLR9 agonists?

Journal: Journal of hepatology

Published: June 24, 2022

Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?

Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?

Journal: Viruses

Published: May 09, 2022

Showing 1-12 of 46

Last Updated: 09/26/2026